April 24, 2012 / 6:37 AM / 5 years ago

Grifols Q1 profit doubles on Talecris

MADRID, April 24 (Reuters) - Grifols, the world’s third largest blood products maker, said first quarter net profit doubled to 67.5 million euros ($88.6 million) from a year ago, lifted by contribution from U.S. peer Talecris.

The net profit figure includes financial costs from the $4 billion purchase of Talecris last year.

The Barcelona-based drug company said revenues also benefited from the merger, rising 17.7 percent to 666.7 million euros. ($1 = 0.7619 euros) (Reporting By Tracy Rucinski; Editing by Sonya Dowsett)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below